Biohealth Innovation
GlaxoSmithKline (GSK) has plans to open an approximately $549m (£400m) biotechnology campus in Stevenage, UK, which would possibly create up to 5,000 skilled jobs in the coming five to ten years.
The plan for the new hub was developed in collaboration with Stevenage Bioscience Catalyst (SBC), the UK Government, Stevenage Borough Council and the Local Enterprise Partnership.
Image: GSK’s R&D site in Stevenage, UK. Credit: GSK / Flickr.
Venture capital totals for D.C. area companies got off to a strong start in 2021, and they’re continuing to rise with a new record high through the halfway point of the year.
In the second quarter of 2021, companies in the metro area collectively raised $1.27 billion across 72 deals, according to data from the PitchBook-NVCA Venture Monitor, a quarterly report produced by PitchBook and the National Venture Capital Association with support from Silicon Valley Bank.
Image: Venture capital. ((Photo by Flickr user, used via a Creative Commons license))
Until recently, biotech companies tended to be founded with a focus on a single technology or biological pathway. An early exemplar of this was Genentech, founded in 1976 on the promise of recombinant DNA to generate proteins relevant for human health.1 Proof of concept came with the production of the hormone somatostatin in 1977, and the company made its synthetic insulin breakthrough in 1978, alleviating the need to harvest the protein from animal pancreases.
The news: Johns Hopkins spinoff Bayesian Health has $15 million in VC backing to offer an AI-based clinical decision support platform designed to make health systems’ electronic health records (EHRs) more predictive.
Here’s how it works: The system analyzes EHR-collected patient data and sends providers real-time clinical signals when a critical moment is detected. It targets high-priority areas such as clinical deterioration, sepsis, pressure injury, and transitions of care.
FREDERICK, Md., July 15, 2021 /PRNewswire-PRWeb/ -- Beckham Gumbin Ventures (BGV), a commercial real estate investor and developer, is beginning construction on brand new R&D laboratory spec suites and amenities at Ballenger Bio (321 Ballenger Center Drive) in Frederick, Maryland. Ballenger Bio will offer several 3,000 to 7,000 SF R&D laboratory spec suites, with the ability to combine up to 37,000 SF of contiguous space on a single floor. Building such spec labs will allow for growing biotech companies to focus on their business as opposed to construction costs and timelines.
DNA-modified cells can behave unpredictably in the body and there is a risk that they could proliferate uncontrolled, cause severe toxicities, and even survive unchecked for months or years. Cartesian uses its platform technology to engineer RNA into cells, making time-controlled changes. The company is developing treatments for cancer, respiratory conditions, and autoimmune diseases such as myasthenia gravis. We spoke to Murat Kalayoglu, president and CEO of Cartesian, about its RNA-engineered cell therapies, how they work and how the company is pushing the use of cell therapies beyond cancer.
Image: https://globalgenes.org
If you are interested in pediatric medical device innovation or alternative solutions to surgery such as focused ultrasound, these two topics will merge at the Pediatric Device Innovators Forum, July 22, from 2 – 3:30 p.m. This free livestream event, hosted by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), features clinical, regulatory and reimbursement experts discussing the topic “Focused Ultrasound for Pediatric Indications.”
Image: https://medcitynews.com
Montgomery County, Maryland, home of the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and more than 480 life sciences companies, continues its momentum as a magnet for new life sciences development with a major surge in leasing and investment. With rising demand and just 5.2% availability for the county’s existing lab space, an additional 1.6 million square feet (SF) of lab space is in development—joining the current 10.6 million SF of total lab inventory already in Montgomery County.
In May 2021, American Gene Technologies (AGT), a clinical-stage biotechnology company, announced the treatment of the first participant in its Phase I clinical trial to evaluate the safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused once with their own CD4 T cells that were enriched, for cells capable of reacting to HIV, and genetically modified to resist infection. This is a first-in-human study for AGT103-T. The primary endpoint is safety; testing related to secondary endpoints evaluates responses to treatment including changes in the immune response to HIV. This video explains AGT's research and HIV cure program strategy.
Lab Space industry analysis included the latest data on revenue numbers, product information and earnings of the major firms. The data includes a breakdown of earnings for the Lab Space international marketplace and a forecast for exactly that same period. This report also includes the most important business strategies that have been identified by the key players in the global Lab Space marketplace. The report also highlights the risks and strengths of key competitors in the global Lab Space market. The market’s vital information is provided by the study on Worldwide Lab Space Market 2021. This report covers all the current facts about Lab Space marketplace, which is crucial in helping to foster this market. A comprehensive assessment of the Lab Space marketplace’s dynamic background is provided at the end of the research.
As the world waits for the results of the investigation into the Wuhan biosafety laboratory and the verification of the COVID-19 origin , experts are turning to other high-security biological research facilities with a renewed interest. The Wuhan lab is only one of many around the world, but where are these other facilities? What are they working on? And most importantly, what security procedures are in place to keep future pandemics from happening?
Image: https://schar.gmu.edu/
Emergent BioSolutions (EBS +1.1%) has gained in morning hours after the company announced that a government agency exercised an option to extend a contract term related to its supply of Smallpox vaccine into the U.S. Strategic National Stockpile (SNS). The Office of the Assistant Secretary for Preparedness and Response (“ASPR”), part of the U.S. Department of Health and Human Services (“HHS”), has modified the contract with the exercise of the second of nine annual contract term extension options, the company said.
Image: https://seekingalpha.com
The deal is expected to close this calendar year.
With the opening of its state-of-the-art facility in Rockville in 2017, GSK has been strengthening its manufacturing presence in the US. As a result, the site’s portfolio of programs and bulk production has been growing steadily, with many immediate full-time job openings at the site. BioBuzz recently hosted a Virtual Recruitment Event for job-seekers to learn more about the various roles at GSK Rockville BioPharm, its work culture, and what the company is looking for in prospective employees.
Improving university/corporate research partnerships is key to advancing US competitiveness. Reform of the IRS rules surrounding corporate sponsored research taking place in university facilities funded by tax-exempt bonds has long been sought by the higher education community and will stimulate more public-private partnerships. With Congress considering new ways to fund research through a new NSF Technology Directorate and the possibility of a large infrastructure package, an opportunity is now open for Congress to address these long-standing reforms in IRS rules.
BUFFALO, N.Y.--(BUSINESS WIRE)--Emerge Capital Management (“Emerge”) has officially launched EMPWR, an emerging managers program. Emerge’s EMPWR program includes a roster of elite, emerging portfolio managers with a special focus on women portfolio managers. It provides full back-office support, platform support, and ESG monitoring dedicated to high performance.
NEWARK, Del., July 14, 2021 /PRNewswire/ -- Today, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) confirms that it has received $153M in new funding from the National Institute of Standards and Technology (NIST) as announced by U.S. Commerce Secretary Gina Raimondo at NIIMBL's National Meeting in Washington, DC. The two awards include $70M to continue federal funding for NIIMBL for an additional five years and an additional $83M for coronavirus response projects under the American Rescue Plan (ARP).
BUFFALO, N.Y.--(BUSINESS WIRE)--Emerge Capital Management (“Emerge”) has officially launched EMPWR, an emerging managers program. Emerge’s EMPWR program includes a roster of elite, emerging portfolio managers with a special focus on women portfolio managers. It provides full back-office support, platform support, and ESG monitoring dedicated to high performance.
“What's important is that we are focusing on top performing managers who would earn their place at the table not just because they are wonderful, talented women, but because they are strong credible portfolio managers” Tweet this
BALTIMORE, July 14, 2021 /PRNewswire/ -- CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System, the world's first and only ultrasound gastrostomy system that allows physicians to place gastrostomy tubes at the point of care, using solely ultrasound imaging.
The PUMA System™ is a new category of minimally invasive devices, enabling ultrasound to be used for procedures in hollow organs of the body where previously it was impossible or unsafe to do so. The first application of the PUMA platform technology, the PUMA-G System, is an FDA-cleared procedural kit allowing bedside clinicians, rather than consultant specialists, to place gastrostomy tubes using solely ultrasound and their existing skill sets and team. With CE Mark approval, the PUMA-G System now has the potential to improve efficiency, safety, and cost-effectiveness on an international level. CoapTech plans to begin a targeted launch in Europe later this year.
During this special webinar panel, we will be focusing on EMPWR’s private equity and private debt sleeve. We will have three private fund managers join us and present how their private, impact funds can improve the quality of life around the world. Emerge’s EMPWR Program has a talented roster of sub-advisors that features a special focus on women private fund leaders.
The federal lab system is an enormous, $50 billion-plus enterprise of internal research and development (R&D) across the United States. As governments around the world, including China, pour billions of dollars into advanced technologies, it is imperative that we use our nation’s federal lab ecosystem as effectively as possible.
However, because federal labs have varying legal authorities, missions, and cultures, their records of local economic engagement and technology commercialization vary considerably. Universities, by contrast, have demonstrated a strong record of supporting regional innovation ecosystems through use of place (creating incubators, research parks, and adjacent innovation districts), talent (allowing university researchers to be involved with private-sector technology under approved and managed relationships), and innovation (using intermediary university foundations to take on business aspects of technology commercialization).
THE PAST YEAR HAS BEEN ONE OF SIGNIFICANT GROWTH FOR FREDERICK'S LIFE SCIENCE SECTOR.
We compiled a list of some of the major local expansion and success stories below.
BIOFACTURA
In February 2021, BioFactura announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA) as part of BioFactura’s prime contract valued at up to $67.4 million for the advanced development of a smallpox biodefense therapeutic. While smallpox was declared eradicated in 1980 by the World Health Organization after an extensive vaccination campaign, the threat of bioterrorism and/or inadvertent release remains. This product has the potential to fulfill an unmet need in preparedness, augment current medical countermeasures and guard against potential resistance.
As the U.K. looks to boost the economy after a major COVID hit—and the looming spotlight of Brexit—the government is creating a new £1 billion public-private partnership in life sciences.
British Patient Capital, the commercial arm of the U.K. government’s British Business Bank, is kickstarting the program, funneling £200 million to “specialist funds” designed to “unlock the potential of innovative U.K. life sciences companies so that they can grow their operations and create high-skilled jobs in the U.K.,” according to the government.
Image: Current Prime Minister Boris Johnson, when Mayor of London last decade, created new life sciences hubs and investment plans. (UK Pool via AP via Newscred)
These are the 50 winners of the Washington Business Journal and DC Inno Fire Awards of 2021.
Image: We're recognizing 50 D.C.-area companies, people and organizations on fire. CAT FRANCIS, AMERICAN INNO
Rockville, Md. — Montgomery County, Maryland, home of the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and more than 480 life sciences companies, continues its momentum as a magnet for new life sciences development with a major surge in leasing and investment. With rising demand and just 5.2% availability for the county’s existing lab space, an additional 1.6 million square feet (SF) of lab space is in development—joining the current 10.6 million SF of total lab inventory already in Montgomery County.
Eight hospitals and health systems have opened or announced plans to establish new centers focused on healthcare innovation this year.
Editor's note: The innovation center launches are listed in the order they were reported.
1. Cleveland Clinic in January said it plans to launch a new infectious disease research center through the new $500 million Cleveland Innovation District backed by the state of Ohio and JobsOhio. The health system in March also partnered with IBM to create a healthcare artificial intelligence discovery center.
2. Harvard University and the Massachusetts Institute of Technology's joint biological innovation center secured $76 million and signed a lease for a new facility in Watertown, Mass., in January.
George Mason University, the largest public research university in Virginia, has a strong tradition of conducting research of consequence, from our pioneering work in cybersecurity to developing new ways of testing for COVID-19.
Since earning our R1 designation for “very high research” from Carnegie in 2016 and joining the elite group of the 131 best U.S. research institutions, our research enterprise has grown rapidly, reaching more than $200 million in funding in 2020, an all-time high for the university.
The formula for launching a machine learning company in health care looks something like this: Build a model, test it on historical patient data in a computer lab, and then start selling it to hospitals nationwide.
Suchi Saria, director of the machine learning and health care lab at Johns Hopkins University, is taking a different approach. Her company, Bayesian Health, is coming out of stealth mode on Monday by publishing a prospective study on how one of its lead products — an early warning system for sepsis — impacted the care of current patients in real hospitals.
Image: Suchi Saria, the chief executive officer of Bayesian Health. COURTESY SUCHI SARIA
Are you a biohealth start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs on one of the following dates. Pre-registration is required; Sign up here tinyurl.com/EIRfeedback
For questions/more information, contact BHI.
Quantum computing could change the world. It could transform medicine, break encryption and revolutionise communications and artificial intelligence. Companies like IBM, Microsoft and Google are racing to build reliable quantum computers. China has invested billions.
Recently, Google claimed that it had achieved quantum supremacy – the first time a quantum computer has outperformed a traditional one. But what is quantum computing? And how does it work?
What is quantum computing? Let’s start with the basics.
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 1, 2021 /PRNewswire/ — Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing. This round of funding was led by Rotating Boulder Fund, an investor that has been supporting the company since its Series B round, with participation from existing investors and a well-recognized syndicate of new investors.
Development veteran Tom Sadowski has been appointed to take over Maryland's quasi-public economic development agency this summer.
Sadowski will take over the executive director role from Robert Brennan, who is retiring at the end of July. Sadowski is currently vice chancellor for economic development at the University System of Maryland, a post he has held for five years. Prior to that, he led the Economic Alliance of Greater Baltimore, a nonprofit business group downtown, for eight years.
Image: Tom Sadowski was just selected in a national search to head the Maryland Economic Development Corp. following the retirement of Robert Brennan. JASON WILLIAMS
If a virtual world has ever left you feeling nauseous or disorientated, you're familiar with cybersickness, and you're hardly alone. The intensity of virtual reality (VR)--whether that's standing on the edge of a waterfall in Yosemite or engaging in tank combat with your friends--creates a stomach-churning challenge for 30-80% of users.
Image: A test subject experiences a potentially stomach-churning virtual reality fly- through of a space station while her brain activity is monitored. CREDIT Maryland Blended Reality Center
Expanded offerings will help regulated life science companies strengthen the supply chain for safe, quality medicines, and medical devices that are critical to patients
Rockville, MD, July 7, 2021 – United States Pharmacopeia (USP), an independent, scientific nonprofit organization, is pleased to announce the acquisition of Pharmatech Associates, Inc. By adding Pharmatech Associates expertise, USP further advances its more than 200-year mission to help ensure access to quality medicines by extending services that assist manufacturers to meet global quality standards across the drug and product lifecycle.
The global medicine supply chain is a complex marketplace of manufacturers, suppliers, and distributors from many countries. Making it more resilient requires a multi-faceted approach. The acquisition of Pharmatech supports our commitment to expand our capabilities to strengthen the supply chain of quality medicines, builds on our longstanding work with regulators and manufacturers globally to solve some of the most critical and challenging problems in the industry, and helps ensure patients have access to the medicines that they need. Pharmatech helps manufacturers satisfy global regulatory requirements to bring products to market, scale up manufacturing, effectively manage quality control, and remediate quality problems in a rapidly changing environment.
The BioHealth Capital Region Forum is free Virtual 2 Half-Day event for executive-level biotech leaders. The theme of the forum this year is "Big Data...Big Data...Converging" with panels on Big Data in Biotech, nfectious Diseases, Developing Talent, Regional Real Estate, IP Analysis and Protection, Funding, and a Fire Side Chat with Dr. Anthony Fauci, NIAID Director.
The 7th Annual BioHealth capital Region Forum is organized by event partners - Association of University Research Parks, AstraZeneca, BioHealth Innovation, BRAINBox Solutions, Inc, Children’s National Hospital, Emergent BioSolutions, George Mason University, Johnson & Johnson Innovation – JLABS @ Washington, DC, Maryland Department of Commerce, and Virginia Bio. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. Please join us for our 7th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow. We hope you’re able to join us!